Braxia Scientific Corp.
BRAXF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | -0.00 | 0.00 |
| FCF Yield | -140.79% | -43.20% | -6.75% | -1.53% |
| EV / EBITDA | -0.37 | -0.29 | -0.72 | -6.43 |
| Quality | ||||
| ROIC | -408.30% | -77.70% | -65.90% | -1.23% |
| Gross Margin | 9.12% | -220.66% | -286.70% | -4,219.81% |
| Cash Conversion Ratio | 0.56 | 0.37 | 0.06 | 1.67 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.17% | 1,814.29% | 1,002,682.91% | 59,527.32% |
| Free Cash Flow Growth | -82.71% | 10.52% | -1,355.74% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.10 | 1.19 | 0.12 | 0.46 |
| Interest Coverage | -419.27 | -1,445.46 | -3,230.63 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 197.35 | 0.00 | 0.00 | 0.08 |
| Cash Conversion Cycle | -151.56 | 4.78 | -143.88 | 360,266.54 |